Ellen Strahlman Appointed Chief Medical Officer at GlaxoSmithKline

Wednesday, September 10, 2008 General News J E 4
PHILADELPHIA, Sept. 9 Ellen Strahlman, M.D.,M.H.Sc., has been appointed Chief Medical Officer (CMO) at GlaxoSmithKline(NYSE: GSK).

Ellen joins GSK from Pfizer Inc. where she was Vice President, Licensing,Worldwide Business Development. During her career, Ellen has worked in avariety of roles including Chief Executive Officer of Virogen Limited, abiotechnology company; Chief Medical Officer and Global Head of R&D for Bausch& Lomb, a pharmaceutical company; and as a senior medical officer for the USgovernment at the National Eye Institute at the National Institutes of Health.She also has worked in leadership roles at Merck and Novartis.

An ophthalmologist, Ellen was appointed this year as the industryrepresentative to the Food and Drug Administration/Center for Drug Evaluationand Research (CDER) Dermatologic & Ophthalmic Drug Advisory Committee. Shealso serves on the Columbia University Medical & Science Technology Counciland the Board of the Foundation of the American Academy of Ophthalmology.

She has a Bachelor of Arts degree in biochemistry and mathematics fromHarvard University. She earned her medical degree at the Johns HopkinsUniversity School of Medicine, where she completed her internship in generalsurgery and residency in ophthalmology. She also has a Master of HeathSciences' degree in epidemiology and statistics from the Bloomberg School ofPublic Health at Johns Hopkins.

The Chief Medical Officer is the most senior physician leader of thecompany with primary responsibility for matters of patient safety, generalmedical governance, ethics and integrity, medical information, andinvestigation involving human subjects relating to any GSK products(pharmaceutical, biologicals and consumer healthcare medicinal products) indevelopment or on the market.

"This role unquestionably represents one of the most important physicianleadership opportunities within the global biopharmaceutical industry," saidGSK R&D Chairman Moncef Slaoui. "The depth of Ellen's medical expertise, hergeneral management and business development experience and proven leadershipskills make her ideally suited to take on the challenges of this criticalrole."

GlaxoSmithKline -- one of the world's leading research-basedpharmaceutical and healthcare companies -- is committed to improving thequality of human life by enabling people to do more, feel better and livelonger.

SOURCE GlaxoSmithKline


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Competing Colorado Springs Health Systems Look to ...
TCOM Graduates Score Highest in Nation on Board Ex...